Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

31.53B

Market cap31.53B

Price-Earnings ratio

35.74

Price-Earnings ratio35.74

Dividend yield

—

Dividend yield—

Average volume

1.16M

Average volume1.16M

High today

$212.18

High today$212.18

Low today

$205.80

Low today$205.80

Open price

$210.02

Open price$210.02

Volume

807.98K

Volume807.98K

52 Week high

$219.72

52 Week high$219.72

52 Week low

$127.00

52 Week low$127.00

Stock Snapshot

The current Biogen(BIIB) stock price is $206.63, with a market capitalization of 31.53B. The stock trades at a price-to-earnings (P/E) ratio of 35.74.

On 2026-08-05, Biogen(BIIB) stock moved within a range of $205.80 to $212.18. With shares now at $206.63, the stock is trading +0.4% above its intraday low and -2.6% below the session's peak.

Trading activity shows a volume of 807.98K, compared to an average daily volume of 1.16M.

The stock's 52-week range extends from a low of $127.00 to a high of $219.72.

BIIB News

Investor's Business Daily 11h

Biogen Stock: How To Find & Own America's Greatest Opportunities - Investor's Business Daily

...

TipRanks 3d

Biogen price target raised to $215 from $200 at Citi

Citi raised the firm’s price target on Biogen (BIIB) to $215 from $200 and keeps a Neutral rating on the shares. The firm updated models in the biotechnology sp...

Simply Wall St 6d

Why Biogen Is Up 5.8% After Q2 Revenue Beat And Raised 2026 Guidance - And What's Next

Biogen Inc. has reported its second-quarter 2026 results, with revenue rising to US$2.74 billion from US$2.65 billion a year earlier while net income dropped sh...

Analyst ratings

64%

of 36 ratings

Buy

63.9%

Hold

33.3%

Sell

2.8%

More BIIB News

TipRanks 7d

Biogen Earnings Call: Growth Engines Offset Near-Term Drag

Biogen Inc. ((BIIB)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing tools with Tip...

Nasdaq 7d

Why Biogen Stock Topped the Market Today

Key Points It handily beat analyst estimates on both the top and bottom lines. Investors didn't even mind a cut in adjusted net income guidance. 10 stocks we...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.